Edesa Biotech, Inc. — Director's Dealing 2018

Mar 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stellar Biotechnologies, Inc. (SBOT)
CIK: 0001540159
Period of Report: 2018-02-22

Reporting Person: MORSE DANIEL E. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-22	Common Shares, without par value	S	7800	$0.784	Disposed	28866	Indirect
2018-02-26	Common shares, without par value	S	7000	$0.790	Disposed	21866	Indirect
2018-02-28	Common shares, without par value	S	7000	$0.790	Disposed	14866	Indirect
2018-03-09	Common shares, without par value	S	7000	$0.805	Disposed	7866	Indirect
2018-03-12	Common shares, without par value	S	3500	$0.797	Disposed	4366	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-12	Share Option (Right to Buy)	$0.84	A	2500	Acquired	2025-03-12	Common Shares (2500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, without par value	194523	Direct

Footnotes

F1: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019.